Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017550 · ClinicalTrials.gov registry record · Phase 2
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00017550: Completed Phase 2 study, sponsored by Genzyme, a Sanofi Company.
NCT00017550 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017550, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome. PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.
Interventions
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
What the finished NCT00017550 record still lists
NCT00017550 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which anti-thymocyte globulin is the first listed.
NCT00017550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00017550 about?
NCT00017550 is a clinical study titled "Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome. PURPOSE: Randomized phase II tri...
What is the current status of trial NCT00017550?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-09. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00017550?
The interventions under investigation include: anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017550?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia